Bibliographical noteFunding Information:
Nicholas E. Ingraham is supported by the NIH NHLBI T32HL07741 grant.
3. JAS: Site PI of a phase 2 RCT investigating HCQ for the prevention of rheumatoid arthritis (funded by NIH/NIAID/Autoimmune Centers of Excellence) and has performed consultancy for Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum unrelated to this work.
- Evidence-based medicine